International Stem Cell Business Summary

International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology company that generates revenue through a dual-track model of commercial product sales and long-term therapeutic development. The company operates through three primary business segments: the Biomedical market, which sells human cell-based research products via its subsidiary Lifeline Cell Technology; the Anti-aging market, which commercializes proprietary skin care products through Lifeline Skin Care; and the Therapeutic market, focused on its proprietary human parthenogenetic stem cell (hpSC) platform. As of late 2025, the company reported trailing twelve-month revenues of approximately $9.4 million, driven largely by its commercial subsidiaries. ISCO competes directly with regenerative medicine firms such as Lineage Cell Therapeutics, Pluri Inc., Mesoblast, and Fate Therapeutics, positioning itself as a niche leader by utilizing unfertilized human eggs to create pluripotent stem cells that avoid the ethical controversies of embryonic cells while offering superior immune-matching capabilities for large populations. ISCO is led by Chief Executive Officer and Co-Chairman Dr. Andrey Semechkin, a specialist in system analysis and strategic planning from the Russian Academy of Sciences who holds a majority 53.3% stake in the company. The scientific core is headed by Dr. Russell Kern, who serves as Executive Vice President, Chief Scientific Officer, and Principal Financial Officer; Dr. Kern is a recognized expert in medical genetics and neurobiology, having pioneered the company’s method for deriving neural stem cells for Parkinson’s disease treatments. The leadership team also includes Rebecca McGee, President of Lifeline Cell Technology, who has overseen the subsidiary’s growth since 2006. The board is anchored by Co-Chairman Donald Wright, a veteran of emerging growth companies, and Independent Director Paul Maier, formerly the CFO of Ligand Pharmaceuticals. This leadership group combines deep academic pedigree in stem cell biology with extensive experience in biopharmaceutical commercialization and corporate governance.